PCNA and cystic kidney disease: GA-A downregulates the Ras/MAPK signaling pathway in a dose-dependent manner, inhibits the expression of proliferating cell nuclear antigen (PCNA), alleviates the growth and progression of renal cysts, and delays the progression of autosomal dominant polycystic kidney disease (ADPKD) [105].